Neuren Pharmaceuticals Limited
NURPF
$10.97
-$1.31-10.67%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 43.67M | 44.90M | 2.64M | 2.64M | 35.61M |
| Total Depreciation and Amortization | 3.60K | 3.70K | 3.60K | 3.60K | 3.60K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.00M | 3.09M | -374.00K | -373.20K | 1.28M |
| Change in Net Operating Assets | -43.66M | -44.89M | -9.04M | -9.02M | 8.74M |
| Cash from Operations | 3.02M | 3.10M | -6.77M | -6.75M | 45.64M |
| Capital Expenditure | -2.30K | -2.30K | -1.00K | -1.00K | -7.20K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1.08M | 1.11M | 277.80K | 277.20K | -53.49M |
| Cash from Investing | 1.07M | 1.10M | 276.80K | 276.20K | -53.50M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 0.00 | 830.00K | 830.00K | 1.27M |
| Repurchase of Common Stock | -5.21M | -5.21M | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | -4.50K | -4.50K | -5.50K |
| Cash from Financing | -3.40M | -3.49M | 544.00K | 542.90K | 821.80K |
| Foreign Exchange rate Adjustments | -505.70K | -520.00K | 1.16M | 1.16M | 103.30K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 189.60K | 195.00K | -4.79M | -4.78M | -6.94M |